Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

Inclusion Criteria: * Body mass index (BMI)\> 25 kg/m² Exclusion Criteria: * Absence of stable weight (variation \< 5 kg) within three months prior to screening visit), * Absence of effective contraceptive method for females of childbearing potential, * Presence of treated or untreated type 1 or type 2 diabetes, * Systolic blood pressure \> 165 mm Hg and/or diastolic blood pressure \> 105 mm Hg on 2 consecutive visits from the screening to the inclusion visit, * Presence of secondary hypertension, * Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint (presence of any clinically significant endocrine disease according to the Investigator, obesity of known endocrine origin...) * Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study, * Presence of any clinically significant abnormality according to the Investigator on the ECG performed on the inclusion visit. * Presence or history of cancer within the past five years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer. * Related to previous or concomitant medications : * Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc). * Antidiabetic drugs. * Related to laboratory findings: * Positive test for hepatitis B surface antigen and/or hepatitis C antibody. * Abnormal TSH level (TSH \> ULN or \< LLN). * Positive urine pregnancy test.